SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Nuvilex, Inc. (OTCQB: NVLX) described today potential advantages of cell encapsulation technology for use in cancer therapies when more than one cancer-fighting drug is used. The cell encapsulation technology platform forms the basis for Nuvilex’s recently acquired pancreatic cancer treatment.
